The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States
David P. Durham(Yale University), Jeffrey P. Townsend(Yale University), Elamin H. Elbasha(Merck & Co., Inc., Rahway, NJ, USA (United States)), R. Douglas Bruce, Sílvia Vilarinho(Yale University), Alison P. Galvani(Yale University), Laura Skrip(London School of Hygiene & Tropical Medicine)
Cited by 55
Related Papers
Estimating GFR Using Serum Cystatin C Alone and in Combination With Serum Creatinine: A Pooled Analysis of 3,418 Individuals With CKD
|American Journal of Kidney Diseases|2008|1k
Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees
|The Lancet|2016|648
A review and agenda for integrated disease models including social and behavioural factors
|Nature Human Behaviour|2021|227
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
|Annals of Oncology|2016|209
Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study
|The Lancet Public Health|2021|169